Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Endothelial Cells and SARS-CoV-2: An Intimate Relationship

Version 1 : Received: 7 October 2020 / Approved: 12 October 2020 / Online: 12 October 2020 (09:41:20 CEST)

A peer-reviewed article of this Preprint also exists.

Barbosa, L. C.; Gonçalves, T. L.; de Araujo, L. P.; Rosario, L. V. de O.; Ferrer, V. P. Endothelial Cells and SARS-CoV-2: An Intimate Relationship. Vascular Pharmacology, 2021, 137, 106829. https://doi.org/10.1016/j.vph.2021.106829. Barbosa, L. C.; Gonçalves, T. L.; de Araujo, L. P.; Rosario, L. V. de O.; Ferrer, V. P. Endothelial Cells and SARS-CoV-2: An Intimate Relationship. Vascular Pharmacology, 2021, 137, 106829. https://doi.org/10.1016/j.vph.2021.106829.

Abstract

Angiotensin-converting enzyme 2 (ACE2) is an important player of the renin-angiotensin-aldosterone system (RAAS) in regulating the conversion of angiotensin II into angiotensin (1-7). While expressed on the surface of human cells, such as lung, heart, kidney, neurons, and endothelial cells (EC), ACE2 is the entry receptor for SARS-CoV-2. Here, we would like to highlight that ACE2 is predominant on the EC membrane. Many of coronavirus disease 2019 (COVID-19) symptoms have been associated with the large recruitment of immune cells, directly affecting EC. Additionally, cytokines, hypoxia, and complement activation can trigger the activation of EC leading to the coagulation cascade. The EC dysfunction plus the inflammation due to SARS-CoV-2 infection may lead to abnormal coagulation, actively participating in thrombo-inflammatory processes resulting in vasculopathy and indicating poor prognosis in patients with COVID-19. Considering the intrinsic relationship between EC and the pathophysiology of SARS-CoV-2, EC-associated therapies such as anticoagulants, fibrinolytic drugs, immunomodulators, and molecular therapies have been proposed. In this review, we will discuss the role of EC in the lung inflammation and edema, in the disseminate coagulation process, ACE2 positive cancer patients, and current and future EC-associated therapies to treat COVID-19.

Keywords

endothelial cells; SARS-CoV-2; ACE2; inflammation; coagulation

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.